TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations is a research paper (2024). On theSindex it has a DataRank of 0.687. It has been cited 14 times, with 13 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.281
From 10 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 13 citers.
Sidney Kimmel Comprehensive Cancer Center
Grant: P30 CA006973
NIH
Clovis Oncology
NIH
Clovis Oncology
FWCI
3.16
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords